223 related articles for article (PubMed ID: 35963244)
1. SARS-CoV-2 spike N-terminal domain modulates TMPRSS2-dependent viral entry and fusogenicity.
Meng B; Datir R; Choi J; ; Bradley JR; Smith KGC; Lee JH; Gupta RK
Cell Rep; 2022 Aug; 40(7):111220. PubMed ID: 35963244
[TBL] [Abstract][Full Text] [Related]
2. Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity.
Meng B; Abdullahi A; Ferreira IATM; Goonawardane N; Saito A; Kimura I; Yamasoba D; Gerber PP; Fatihi S; Rathore S; Zepeda SK; Papa G; Kemp SA; Ikeda T; Toyoda M; Tan TS; Kuramochi J; Mitsunaga S; Ueno T; Shirakawa K; Takaori-Kondo A; Brevini T; Mallery DL; Charles OJ; ; ; ; Bowen JE; Joshi A; Walls AC; Jackson L; Martin D; Smith KGC; Bradley J; Briggs JAG; Choi J; Madissoon E; Meyer KB; Mlcochova P; Ceron-Gutierrez L; Doffinger R; Teichmann SA; Fisher AJ; Pizzuto MS; de Marco A; Corti D; Hosmillo M; Lee JH; James LC; Thukral L; Veesler D; Sigal A; Sampaziotis F; Goodfellow IG; Matheson NJ; Sato K; Gupta RK
Nature; 2022 Mar; 603(7902):706-714. PubMed ID: 35104837
[TBL] [Abstract][Full Text] [Related]
3. Impact of SARS-CoV-2 Spike Mutations on Its Activation by TMPRSS2 and the Alternative TMPRSS13 Protease.
Stevaert A; Van Berwaer R; Mestdagh C; Vandeput J; Vanstreels E; Raeymaekers V; Laporte M; Naesens L
mBio; 2022 Aug; 13(4):e0137622. PubMed ID: 35913162
[TBL] [Abstract][Full Text] [Related]
4. SARS-CoV-2 and SARS-CoV Spike-Mediated Cell-Cell Fusion Differ in Their Requirements for Receptor Expression and Proteolytic Activation.
Hörnich BF; Großkopf AK; Schlagowski S; Tenbusch M; Kleine-Weber H; Neipel F; Stahl-Hennig C; Hahn AS
J Virol; 2021 Apr; 95(9):. PubMed ID: 33608407
[TBL] [Abstract][Full Text] [Related]
5. Differentiating Cell Entry Potentials of SARS-CoV-2 Omicron Subvariants on Human Lung Epithelium Cells.
Katte RH; Ao Y; Xu W; Han Y; Zhong G; Ghimire D; Florence J; Tucker TA; Lu M
Viruses; 2024 Mar; 16(3):. PubMed ID: 38543757
[TBL] [Abstract][Full Text] [Related]
6. Metalloproteinase-Dependent and TMPRSS2-Independent Cell Surface Entry Pathway of SARS-CoV-2 Requires the Furin Cleavage Site and the S2 Domain of Spike Protein.
Yamamoto M; Gohda J; Kobayashi A; Tomita K; Hirayama Y; Koshikawa N; Seiki M; Semba K; Akiyama T; Kawaguchi Y; Inoue JI
mBio; 2022 Aug; 13(4):e0051922. PubMed ID: 35708281
[TBL] [Abstract][Full Text] [Related]
7. SARS-CoV-2 Omicron Specific Mutations Affecting Infectivity, Fusogenicity, and Partial TMPRSS2-Independency.
Strobelt R; Broennimann K; Adler J; Shaul Y
Viruses; 2023 May; 15(5):. PubMed ID: 37243215
[TBL] [Abstract][Full Text] [Related]
8. Distinctive Roles of Furin and TMPRSS2 in SARS-CoV-2 Infectivity.
Essalmani R; Jain J; Susan-Resiga D; Andréo U; Evagelidis A; Derbali RM; Huynh DN; Dallaire F; Laporte M; Delpal A; Sutto-Ortiz P; Coutard B; Mapa C; Wilcoxen K; Decroly E; Nq Pham T; Cohen ÉA; Seidah NG
J Virol; 2022 Apr; 96(8):e0012822. PubMed ID: 35343766
[TBL] [Abstract][Full Text] [Related]
9. Intrinsic D614G and P681R/H mutations in SARS-CoV-2 VoCs Alpha, Delta, Omicron and viruses with D614G plus key signature mutations in spike protein alters fusogenicity and infectivity.
Khatri R; Siddqui G; Sadhu S; Maithil V; Vishwakarma P; Lohiya B; Goswami A; Ahmed S; Awasthi A; Samal S
Med Microbiol Immunol; 2023 Feb; 212(1):103-122. PubMed ID: 36583790
[TBL] [Abstract][Full Text] [Related]
10. Dynamics of SARS-CoV-2 Spike Proteins in Cell Entry: Control Elements in the Amino-Terminal Domains.
Qing E; Kicmal T; Kumar B; Hawkins GM; Timm E; Perlman S; Gallagher T
mBio; 2021 Aug; 12(4):e0159021. PubMed ID: 34340537
[TBL] [Abstract][Full Text] [Related]
11. The Transmembrane Protease Serine 2 (TMPRSS2) Non-Protease Domains Regulating Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Spike-Mediated Virus Entry.
Strobelt R; Adler J; Shaul Y
Viruses; 2023 Oct; 15(10):. PubMed ID: 37896901
[TBL] [Abstract][Full Text] [Related]
12. The Spike-Stabilizing D614G Mutation Interacts with S1/S2 Cleavage Site Mutations To Promote the Infectious Potential of SARS-CoV-2 Variants.
Gellenoncourt S; Saunders N; Robinot R; Auguste L; Rajah MM; Kervevan J; Jeger-Madiot R; Staropoli I; Planchais C; Mouquet H; Buchrieser J; Schwartz O; Chakrabarti LA
J Virol; 2022 Oct; 96(19):e0130122. PubMed ID: 36121299
[TBL] [Abstract][Full Text] [Related]
13. Spike substitution T813S increases Sarbecovirus fusogenicity by enhancing the usage of TMPRSS2.
Ma Y; Li P; Hu Y; Qiu T; Wang L; Lu H; Lv K; Xu M; Zhuang J; Liu X; He S; He B; Liu S; Liu L; Wang Y; Yue X; Zhai Y; Luo W; Mai H; Kuang Y; Chen S; Ye F; Zhou N; Zhao W; Chen J; Chen S; Xiong X; Shi M; Pan JA; Chen YQ
PLoS Pathog; 2023 May; 19(5):e1011123. PubMed ID: 37196033
[TBL] [Abstract][Full Text] [Related]
14. SARS-CoV-2 Spike Protein Is Capable of Inducing Cell-Cell Fusions Independent from Its Receptor ACE2 and This Activity Can Be Impaired by Furin Inhibitors or a Subset of Monoclonal Antibodies.
Reuter N; Chen X; Kropff B; Peter AS; Britt WJ; Mach M; Überla K; Thomas M
Viruses; 2023 Jul; 15(7):. PubMed ID: 37515187
[TBL] [Abstract][Full Text] [Related]
15. Spike mutations contributing to the altered entry preference of SARS-CoV-2 omicron BA.1 and BA.2.
Hu B; Chan JF; Liu H; Liu Y; Chai Y; Shi J; Shuai H; Hou Y; Huang X; Yuen TT; Yoon C; Zhu T; Zhang J; Li W; Zhang AJ; Zhou J; Yuan S; Zhang BZ; Yuen KY; Chu H
Emerg Microbes Infect; 2022 Dec; 11(1):2275-2287. PubMed ID: 36039901
[TBL] [Abstract][Full Text] [Related]
16. Altered hACE2 binding affinity and S1/S2 cleavage efficiency of SARS-CoV-2 spike protein mutants affect viral cell entry.
Wang K; Pan Y; Wang D; Yuan Y; Li M; Chen Y; Bi L; Zhang XE
Virol Sin; 2023 Aug; 38(4):595-605. PubMed ID: 37343929
[TBL] [Abstract][Full Text] [Related]
17. SARS-CoV-2 Omicron entry is type II transmembrane serine protease-mediated in human airway and intestinal organoid models.
Mykytyn AZ; Breugem TI; Geurts MH; Beumer J; Schipper D; van Acker R; van den Doel PB; van Royen ME; Zhang J; Clevers H; Haagmans BL; Lamers MM
J Virol; 2023 Aug; 97(8):e0085123. PubMed ID: 37555660
[TBL] [Abstract][Full Text] [Related]
18. The impact of S2 mutations on Omicron SARS-CoV-2 cell surface expression and fusogenicity.
Escalera A; Laporte M; Turner S; Karakus U; Gonzalez-Reiche AS; van de Guchte A; Farrugia K; Khalil Z; van Bakel H; Smith D; García-Sastre A; Aydillo T
Emerg Microbes Infect; 2024 Dec; 13(1):2297553. PubMed ID: 38112266
[TBL] [Abstract][Full Text] [Related]
19. Characterization of SARS-CoV-2 Variants B.1.617.1 (Kappa), B.1.617.2 (Delta), and B.1.618 by Cell Entry and Immune Evasion.
Ren W; Ju X; Gong M; Lan J; Yu Y; Long Q; Kenney DJ; O'Connell AK; Zhang Y; Zhong J; Zhong G; Douam F; Wang X; Huang A; Zhang R; Ding Q
mBio; 2022 Apr; 13(2):e0009922. PubMed ID: 35266815
[TBL] [Abstract][Full Text] [Related]
20. Proteolytic activation of SARS-CoV-2 spike protein.
Takeda M
Microbiol Immunol; 2022 Jan; 66(1):15-23. PubMed ID: 34561887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
